Drugmaker Novartis blocked from selling Neupogen copycat until Sept 2

NEW YORK (Reuters) - Novartis AG must wait until Sept. 2 to sell the first biosimilar drug to be approved in the United States, a copycat version of Amgen Inc's $1.2 billion-a-year Neupogen, a U.S. appeals court said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news